A balloon catheter by which a drug can be effectively delivered to living body tissue and a method of manufacturing the balloon catheter, and a treatment method. The balloon catheter is provided on an outer surface of a balloon with a plurality of elongate bodies which are independent crystals of a water-insoluble drug that extend in an elongate form. The elongate bodies have long axes extending in directions along the outer surface of the balloon when the balloon is in a deflated state. Deformation, when the balloon is inflated from the deflated state, of portions on an outer surface side of the balloon to which end portions of the elongate bodies are fixed causes a force to act on the elongate bodies such that the long axes of the elongate bodies approach perpendicularity to the outer surface of the balloon.

A drug delivery balloon (10) has a drug thereon in the form of crystalline particles (12), the drug having a predetermined size distribution. Optionally marker particles (14, 16) are also provided. A texturized coating (18), a cap layer (20) and/or other methods may be used to increase particle loading capacity of the balloon.

A drug delivery balloon (10) has a drug thereon in the form of crystalline particles (12), the drug having a predetermined size distribution. Optionally marker particles (14, 16) are also provided. A texturized coating (18), a cap layer (20) and/or other methods may be used to increase particle loading capacity of the balloon.

Various embodiments disclosed relate to polymer-encapsulated drug particles and a drug-releasing coating including the same, as well as drug-coated balloon catheters for treating, preventing, or reducing the recurrence of strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes the polymer-encapsulated drug particles; or a drug-releasing coating including the polymer-encapsulated drug particles; or a therapeutic agent and a first and/or second additive; or a combination thereof.

A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.

A drug-loaded implanted medical device and a preparation method therefor. The drug-loaded implanted medical device comprises a device body and grooves (2) distributed on the surface of the device body, and at least one of the grooves (2) is loaded with a solid drug (11); the solid drug (11) is a crystal or has a form in which a crystal coexists with an amorphous body. The preparation method is implemented by loading the solid drug (11) into at least one of the grooves (2) by means of solution crystallization.

Medical devices and methods for drying medical devices are disclosed. An example method for drying a medical device may include disposing a medical device within a drying apparatus. The drying apparatus may include a variable frequency microwave heating device. The medical device may include a substrate, the substrate including an active pharmaceutical ingredient and a solvent. The method may also include heating the medical device with the drying apparatus. Heating may evaporate at least a portion of the solvent.

The present invention relates to a suspension for coating of medical devices containing at least one tri-O-acylglycerol, at least one limus active agent in the form of microcrystals and at least one solvent in which the at least one tri-O-acylglycerol dissolves and in which the microcrystals of the at least one limus active agent do not dissolve. Furthermore, the present invention relates to a pmethod for preparing said suspension, a p method for coating a medical device with said suspension, and medical devices coated with at least one tri-O-acylglycerol and at least one microcrystalline limus active agent.

Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, a drug delivery coating is included herein having a base polymeric layer, the base polymeric layer including a hydrophilic polyether block amide copolymer and having a hydrophilic surface. The drug delivery coating can further include a therapeutic agent layer forming an exterior surface the drug delivery coating, the therapeutic agent layer contacting the hydrophilic surface of the base polymeric layer and having a composition different than the base polymeric layer, the therapeutic agent layer including a particulate hydrophobic therapeutic agent and a cationic agent. Other embodiments are also included herein.

A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.